Agios Pharmaceuticals Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of Scott Biller, Ph.D., as Chief Scientific Officer. Dr. Biller joins Agios from Novartis Pharmaceuticals, where he was Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research (NIBR).

Back to news